BIOBRIEF
VYD2311, a monoclonal antibody rather than a vaccine, posted a quieter side effect profile than Pfizer's Comirnaty; Invivyd plans to seek accelerated FDA approval.
VYD2311 is not a vaccine. It is an injected monoclonal antibody, a lab-made protein that delivers ready-made immunity rather than training the body to make its own. That difference is why Invivyd's LIBERTY Phase 3 trial saw a much quieter day-after profile than Pfizer's mRNA Covid vaccine Comirnaty.
The trial randomized 210 healthy adults aged 18–49 across three blinded arms, each receiving two injections. Within six days, 56.5% of VYD2311 recipients reported any treatment-emergent side effect versus 91.4% of Comirnaty recipients (P <0.0001). Solicited systemic symptoms like headache, chills, and fatigue hit 44.1% versus 68.1% (P = 0.008). STAT+ rounds the headline number to 57% versus 91%. The endpoint was tolerability, not infection prevention.
Invivyd says it will seek FDA accelerated approval using LIBERTY plus its pending DECLARATION study, a ~2,400-participant placebo-controlled trial targeting 70%–90% relative risk reduction in clinical Covid. Actual prevention data are not yet in hand. What is in hand is a quieter second path for readers whose mRNA experience was rough, additive to, not a replacement for, the workhorse mRNA option.